Rhythm Pharma Reports Strong IMCIVREE Revenue Growth & March PDUFA Date for Acquired HO

summarizeSummary

Rhythm Pharmaceuticals announced strong preliminary Q4 and full-year 2025 revenue growth for IMCIVREE, alongside key upcoming regulatory and clinical milestones, including a March 2026 PDUFA date for acquired hypothalamic obesity.

check_boxKey Events

• Strong Preliminary Revenue Growth

  Global IMCIVREE sales reached approximately $57 million in Q4 2025, an 11% sequential increase from Q3 2025. Full-year 2025 net product revenues are expected to be approximately $194 million, representing a 50% increase year-over-year from $130 million in FY 2024.

• Key PDUFA Date Set

  The FDA has assigned a PDUFA goal date of March 20, 2026, for the supplemental New Drug Application (sNDA) for setmelanotide in acquired hypothalamic obesity, pending FDA approval for a US launch.

• Multiple Q1 2026 Topline Data Readouts

  The company anticipates announcing topline data in the first quarter of 2026 from the 12-patient Japanese cohort of the setmelanotide Phase 3 trial in acquired HO and from the Phase 3 EMANATE trial evaluating setmelanotide in genetically caused MC4R pathway diseases.

• Positive Prader-Willi Syndrome Data

  Rhythm announced positive preliminary data in December 2025 from an exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi Syndrome (PWS), showing BMI and hyperphagia reductions. Six-month results from 18 patients are expected in the first half of 2026.

auto_awesomeAnalysis

This 8-K filing is highly important as it provides a strong positive update on both Rhythm Pharmaceuticals' commercial performance and its robust clinical pipeline. The preliminary unaudited net product revenues for IMCIVREE demonstrate significant growth, with a 50% year-over-year increase for fiscal year 2025 and an 11% sequential increase in the fourth quarter. This commercial momentum is coupled with critical near-term catalysts, most notably the March 20, 2026 PDUFA goal date for setmelanotide in acquired hypothalamic obesity, which represents a substantial market expansion opportunity. Additionally, the company anticipates multiple topline data readouts in Q1 2026 for other key programs, further de-risking and advancing its pipeline. The positive preliminary data for Prader-Willi Syndrome also adds to the long-term growth potential. Investors should monitor the FDA decision and upcoming data readouts closely, as these events could significantly impact the company's valuation and future trajectory.